A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.

@article{Thiebaud1998A3S,
  title={A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.},
  author={Daniel Thiebaud and J. M. Bigler and S C Renteria and Th. Pache and H. J. Welti and Maria Landry and Peter Burckhardt},
  journal={Climacteric : the journal of the International Menopause Society},
  year={1998},
  volume={1 3},
  pages={202-10}
}
The aim of this study was to investigate the effects of tibolone in the prevention of postmenopausal bone loss over 3 years, and to compare these with the effects of sequential hormone replacement therapy. Forty early postmenopausal women were randomized to a 21-day regimen of conjugated equine estrogens (CEE, Premarin) plus sequential medroxyprogesterone acetate (MPA, Prodafem), or tibolone (Livial) daily. In total, 36 women completed 12 months and were considered for the intent-to-treat… CONTINUE READING